Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

This study has been completed.
Information provided by:
Swedish Orphan Biovitrum Identifier:
First received: October 6, 2003
Last updated: February 27, 2009
Last verified: November 2008

Open label palifermin will be administered to subjects who are at a risk of developing mucositis after radiotherapy and chemotherapy followed by blood stem cell support. The amount of palifermin in the blood following administration will be evaluated. The safety of palifermin administration and its effect on reducing mucositis will also be evaluated.

Condition Intervention Phase
Drug: Palifermin
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Swedish Orphan Biovitrum:

Primary Outcome Measures:
  • To characterize the PK profile of 3 daily intravenous (IV) doses of rHuKGF before total body irradiation (TBI) / high-dose chemotherapy conditioning treatment and after PBPC transplantation

Secondary Outcome Measures:
  • To assess the safety and tolerability of rHuKGF in subjects with hematologic malignancies undergoing TBI and high-dose chemotherapy followed by PBPC transplantation.
  • To assess oral mucositis in subjects receiving rHuKGF.

Study Start Date: December 2001
Detailed Description:

Mucositis is a common side effect to chemotherapy and radiotherapy involving the formation of erythema and ulcerative lesions in the mouth. Mucositis can be serious, resulting in pain requiring interventions such as analgesic medications and the use of parenteral feedings. Currently, no standard therapy is available to prevent or treat mucositis.


Ages Eligible for Study:   18 Years to 76 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  • Patients diagnosed with Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia and Myeloma. - Eligible for treatment with radiation therapy and chemotherapy followed by blood stem cell support.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00070616

Sponsors and Collaborators
Swedish Orphan Biovitrum
Study Director: MD Amgen
  More Information

Responsible Party: Clinical Development, Biovitrum Ab (publ) Identifier: NCT00070616     History of Changes
Obsolete Identifiers: NCT00963170
Other Study ID Numbers: 20010182
Study First Received: October 6, 2003
Last Updated: February 27, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Swedish Orphan Biovitrum:
radiation therapy processed this record on October 19, 2014